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Abstract 
Lactic acid bacteria (LAB) have a long history of safe exploitation by humans, being used for centuries in food produc‑
tion and preservation and as probiotic agents to promote human health. Interestingly, some species of these Gram‑
positive bacteria, which are generally recognized as safe organisms by the US Food and Drug Administration (FDA), are 
able to survive through the gastrointestinal tract (GIT), being capable to reach and colonize the intestine, where they 
play an important role. Besides, during the last decades, an important effort has been done for the development of 
tools to use LAB as microbial cell factories for the production of proteins of interest. Given the need to develop effec‑
tive strategies for the delivery of prophylactic and therapeutic molecules, LAB have appeared as an appealing option 
for the oral, intranasal and vaginal delivery of such molecules. So far, these genetically modified organisms have been 
successfully used as vehicles for delivering functional proteins to mucosal tissues in the treatment of many different 
pathologies including GIT related pathologies, diabetes, cancer and viral infections, among others. Interestingly, the 
administration of such microorganisms would suppose a significant decrease in the production cost of the treatments 
agents since being live organisms, such vectors would be able to autonomously amplify and produce and deliver the 
protein of interest. In this context, this review aims to provide an overview of the use of LAB engineered as a promising 
alternative as well as a safety delivery platform of recombinant proteins for the treatment of a wide range of diseases.
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Background
Most of the existing strategies for the treatment of dis-
eases are focused on the delivery of naked molecules 
with a therapeutic activity, from chemically synthesized 
molecules to recombinant proteins produced in diverse 
platforms such as bacteria, yeast, insect cells and mam-
malian cells, among others [1]. However, these treatments 
require in many cases the use of invasive administration 
methods such as intravenous or subcutaneous injection of 
the molecule of interest to reach the targeted region [2]. 
Moreover, soluble purified proteins and other therapeutic 
compounds frequently show low stability and/or poor 
efficiency in the organism forcing repeated administration 
[2], with the subsequent increase in the amount of needed 
pharmaceutical and the frequent derived increase in tox-
icity and cost of the treatment [2]. In the case of recom-
binant therapeutic proteins produced in microbial hosts, 
biosafety concerns are raised, mainly due to the possible 
remnants of pyrogenic or inflammatory contaminants 
that can trigger undesirable immunogenic responses [3]. 
Given the need to develop an alternative route for the 
administration, as well as a safety delivery platform, lactic 
acid bacteria (LAB) have appeared as an appealing option 
for the production and delivery of therapeutic molecules 
and antigens of interest [4]. This heterogeneous group 
of Gram-positive bacteria, in contrast to Gram-negative 
bacteria such as E. coli, do not contain lipopolysaccarides 
(LPS) attached to the cell membrane. The absence of such 
endotoxins avoids the generation of an anaphylactic shock 
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when LAB are administered in humans [3]. In this regard, 
it should be noted that LAB have a long history of safe use 
by humans, being used for centuries in food production 
and preservation [5–7]. In this context, some strains have 
also a long record in their use as probiotic bacteria pro-
ducer of metabolites and macromolecules able to maintain 
and promote human health [5, 8]. Then, LAB have been 
classified as food grade microorganisms [generally recog-
nized as safe (GRAS) organisms by the US Food and Drug 
Administration (FDA)] and fulfill criteria of the qualified 
presumption of safety (QPS) according to the European 
Food Safety Authority (EFSA). Besides, it is important to 
stress that an exhaustive work has been done in develop-
ing different tools for the recombinant protein produc-
tion using LAB as cell factories [9]. The development of 
these tools has made possible the development of LAB 
able to secrete the protein of interest to the extracellular 
environment, becoming a key aspect when evaluating the 
potential of these bacteria for mucosal targeting of thera-
peutic molecules [4] (Table  1). Alternatively, approaches 
based on protein display anchored to the bacteria cell wall 
have also been tested [10], being a system that, even not 
being as effective as secreted protein in terms of protein 
expression levels, gives a higher protection to the protein 
in front of degrading and denaturing agents (Table 1). In 
consequence, these microorganisms can be used for oral, 
intranasal or vaginal administration for protein delivery 
purposes, minimizing any potential side effect associ-
ated with the classical parenteral or subcutaneous admin-
istration of proteins, simultaneously reducing the dose 
needed.
Although LAB include microorganisms from differ-
ent genus such as Leuconostoc, Lactococcus, Lactoba-
cillus, Pedicoccus and Streptococcus, Lactococcus lactis 
has been the most widely used considering cloning and 
production of recombinant proteins [11]. L. lactis has 
been deeply characterized, being the first one whose 
genome was fully sequenced. In addition, it is an expres-
sion system easy to manipulate with many cloning and 
expression systems available. The most widely used pro-
tein expression system for L. lactis is the NICE (Nisin 
Controlled Expression) system, based on the control 
of a strong nisin inducible promoter (PnisA), which has 
several advantages. The expression of the gene of inter-
est is tightly regulated and high expression levels are 
achieved using a food-grade molecule (nisin) as inducer. 
[12]. Although several proteins with biotechnological or 
biomedical interest produced in L. lactis using induc-
ible plasmids have been proved in both experimen-
tal models and clinical trials [13], a prior induction of 
protein production have been required in these cases 
before the administration of the recombinant bacteria. 
For that reason, other inducible promoters that do not 
require the addition of any external inducer have been 
developed not only for L. lactis, but also for other LAB 
such as Lactobacillus paracasei. These promoters are 
directly induced in situ, for example once bacteria suffer 
environmental stresses such as heat-stress (body tem-
perature is some degrees higher than bacteria optimal 
growth temperature) [14] or acid-stress (because of the 
stomach fluids) [15], enabling the recombinant produc-
tion of the protein of interest without the need for add-
ing an external inducer. In this regard and considering 
that L. paracasei respond to stress by synthesising chap-
erones such as groESL [14], an Stress-Inducible Con-
trolled Expression (SICE) system based on the groESL 
operon promoter has also been described [15]. The 
development of promoters that do not depend on the 
addition of external inducers have allowed to take an 
important qualitative leap towards the use of LAB as 
protein delivery vectors. In this context and aiming to 
take another step forward, constitutive promoters are 
also being extensively studied. These constitutive pro-
moters make possible to get a maintained expression of 
the protein of interest over time without the need of any 
type of inducer. Currently it has been widely explored, 
being possible to find an important number of examples 
that have already been tested for protein delivery pur-
poses specially with L. lactis, but also with L. paracasei, 
Lactobacillus casei, Lactobacillus plantarum, Bifidobac-
terium breve and Streptococcus gordonii (Table 1).
Thus, the use of food grade microorganisms as recom-
binant protein cell factories [9] and delivery platforms at 
the same time, is a promising approach [6, 11]. Briefly, the 
administration of such microorganisms would also suppose 
a significant decrease in the production cost of the drugs 
as being live organisms, these live vectors would be able 
to autonomously synthesize and deliver the prophylactic 
or therapeutic protein of interest. Moreover, it is possible 
to simultaneously produce different proteins in the same 
bacteria [16]. Altogether has turned them into an attrac-
tive alternative not only to intravenous administration of 
naked recombinant proteins, but also to other classical 
delivery systems for mucosal targeting, such as attenuated 
pathogens, liposomes and microparticles [10]. Thus, here, 
is intended to provide an overview of the use of genetically 
modified food grade organisms engineered as attractive 
vehicles for delivering functional proteins to mucosal tis-
sues for the treatment of a wide range of pathologies such 
as GIT related pathologies as well as some types of cancer 
and viral infections, among others (Fig. 1).
Review
Autoimmune diseases
Effective therapeutic approaches for autoimmune dis-
eases like GIT related diseases and diabetes are urgently 
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Table 1 Recombinant proteins produced in LAB for biomedical purposes
LAB Application Recombinant 
protein
Expression vector Promoter Protein display References
Lactococcus lactis IDB Anti‑TNFalpha  
nanobodies
pTREX‑derived P1 (pH dependent) Secreted [22]
Lactococcus lactis IDB Trefoil Factors (TFF) pTREX‑derived P1 (pH dependent) Secreted [23]
Lactococcus lactis IDB Low calcium 
response V (LcrV)







sodA native promoter – [39, 40]
Lactococcus lactis IDB IL‑10 Cromosome inte‑
grated
PthyA (constitutive) Secreted [26]
Lactococcus lactis IDB IL‑27 pT1NX‑derived P1 (pH dependent) Secreted [35]










Lactococcus lactis Type 1 diabetes Pro Insulin/(GAD)‑
65/IL‑10
pT1NX‑derived P1 (pH dependent) Secreted [44]







Lactococcus lactis Type 1 diabetes GAD65 and IA‑2 – – Secreted [46]
Lactococcus lactis Diabetes Single‑chain insulin 
analog, SCI‑57
pNZPnisA:uspSCI‑57 PnisA (inducible) Secreted [41]
Lactococcus lactis Type 2 diabetes Glucagon like pep‑
tide‑1 (GLP‑1)
pUBGLP‑1 P1 (pH dependent) Secreted [42]
Lactococcus lactis Cancer HPV‑16 E7 antigen pLB263 PgroESL (inducible) Secreted [15]
Bifidobacterium 
longum
Breast cancer Cytosine Deaminase pBLES100‑S‑eCD – – [57]
Bifidobacterium 
adolescentis
Cancer Endostatin pBV220‑derived PRPL (thermoinduc‑
ible)
Cytoplasmatic [58]
Bifidobacterium breve Cancer treatment 
study tool
Luciferase pLux MC3 Phelp (constitutive) Cytoplasmatic [59]
Lactococcus lactis Cervical cancer HPV‑16 E7 – PnisA (Inducible) Anchored [61]
Lactococcus lactis Cervical cancer HPV‑16 E7 pMG36e P32 (constitutive) Cytoplasmatic [62]
Lactococcus lactis/
Lactobacillus casei
Cervical cancer HPV‑16 E7 – – Anchored [63]




















VP1 pBBADs‑VP1 – – [109]
Bifidubacterium 
longum
Hepatitis C infection HCV‑NS3 peptide – – Cell anchored [110]




pLB263 PgroESL (inducible) Secreted [15]
Lactobacillus acido-
philus
HIV infection Gag pTRK1035 (Constitutive) Cell anchored [82]
Lactobacillus jensenii HIV infection two‑domain CD4 
(2D CD4) proteins
pOSEL144 P23 (constitutive) Secreted [69]
Lactobacillus casei Tetanus Tetanus toxin frag‑
ment C (TTC)
pLP401‑TTFC P amylase (inducible) Cell anchored [72]
Lactobacillus casei Tetanus Tetanus toxin frag‑
ment C (TTC)
pLP501‑TTFC Pldh (constitutive) Cell anchored [72]
Lactobacillus plan-
tarum
Tetanus Tetanus toxin frag‑
ment C (TTC)
pMEC160 Pldh (constitutive) Cell anchored [70]
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needed and the development of oral formulation is an 
imperative need. Oral administration is the most pre-
ferred route since it is well accepted by patients, becom-
ing a promising alternative for drug delivery of such 
autoimmune diseases.
GIT related diseases: Crohn’s disease and ulcerative colitis
Inflammatory bowel disease (IBD) is an idiopathic 
disorder consisting in the inflammation of the GIT. It 
is believed that this abnormal condition is due to an 
uncontrolled immune response against the gut micro-
flora [17, 18]. Although the underlying cause is still 
unclear [19, 20], it is known that environmental and 
genetic factors have an important role in these com-
plex diseases. Crohn’s disease and ulcerative colitis 
are included in this general IBD definition and the 
patients that suffer these chronic diseases usually 
require lifelong and costly treatments with sever side-
effects. Moreover, in many cases, therapeutic agents 
used fail, and despite medical treatment, surgery is 
needed. In this sense, the use of recombinant microor-
ganisms,  that fulfill the QPS standards, overexpressing 
any molecule able to alleviate inflammation could be 
an attractive and alternative treatment, since their safe 
profile and administration pathway would allow an easy 
incorporation of the treatment to the patient’s routine 
improving their comfort. Some strategies have been 
proposed using proteins such as low-calcium V antigen 
(LcrV) [21], anti-TNFα nanobodies [22], trefoil fac-
tors (TFF) [23], catalase [24, 25] and IL-10 [26] using 
L. lactis as microbial delivery vector (Table 1). All these 
proteins have been successfully produced by the L. lac-
tis platform ameliorating, upon their oral administra-
tion, the inflammatory response of IBD animal models. 
Table 1 continued
LAB Application Recombinant 
protein












Adhesin Hp0410 pMG36e – Cytoplasmatic [76]




Lactococcus lactis Malaria MSP‑119 pL2‑PSGT – Cytoplasmatic [81]












cyst wall protein 2 
(CWP2)
pSMB104 (constitutive) Cell anchored [73]
Lactobacillus zeae Streptococcus 
mutants infection
ScFv protein pLP402‑scFv – Cell anchored [68]




pTREX1 P1 (pH dependent) Cytoplasmatic [113]
Lactobacillus casei SARS‑associated 
coronavirus infec‑
tion
PgsA and spike 
protein
pHAT PHCE (constitutive) Cell anchored [114]
Lactobacillus acido-
philus
Chiken anemia virus VP1 pETacmA1 – Cell anchored [71]
Lactococcus lactis Avian influenza virus hemagglutinin 1 
(HA1)
pMG36e – Cytoplasmatic [91]








Lactobacillus casei Pancreatic necrosis 
virus (IPNV)
VP2/VP3 pG1/pG2 Pxylose (inducible) Secreted [89, 90]
Lactococcus lactis Body weight control Leptin pSEC:lep PnisA (Inducible) – [97]
Saccharomyces 
cerevisiae
Hypercalcemia Salmon calcitonin pAGA2‑sCT PGAL1 (inducible) Cell anchored [115]
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Noteworthy, the success of these approaches is related 
to the delivery of the therapeutic agent at the mucosa 
level. A clear example is provided by the orally admin-
istered L. lactis secreting anti-TNFα nanobodies [22]. 
This nanobody secretion platform has an efficacy simi-
lar to that observed with the established therapy (Inf-
liximab, Remicade), based on the intravenous infusion 
of anti-TNFα [22, 27–30]. However, contrary to what 
occurs by the systemic infusion, the oral administration 
of L. lactis strains secreting anti-TNFα is cost effective 
and lacks adverse effects [22].
LAB with potential in IBD treatment share the objec-
tive of reducing gut inflammation. Nevertheless, depend-
ing on the recombinant protein to be delivered the 
affected pathway differs. Thus, anti-TNFα nanobodies 
would reduce inflammation by neutralizing the action 
of the pro-inflammatory cytokine TNFα. Expression of 
IL-10, which is a regulatory cytokine, would decrease 
inflammation thanks to its antinflammatory activity [26], 
while the use of enzymes such as catalase would act on 
the inflammatory response derived from the presence of 
reactive oxygen species (ROS) [24, 25].
The approach that probably has been more exten-
sively studied is the delivery of IL-10 produced in L. 
lactis. In fact, L. lactis secreting IL-10 has been submit-
ted to clinical trials for the treatment of Crohn disease 
(ClinicalTrials.gov Identifier: NCT00729872) [23, 26, 
31–34]. Nevertheless, and despite the very promis-
ing results observed in mice, the clinical trial revealed 
the mentioned approach inefficient (ClinicalTrials.gov 
Identifier: NCT00729872). This failure is thought as a 
consequence of a low final concentration of IL-10 in the 
GIT. In this regard, it has been recently proposed using 
IL-27, a pleiotropic cytokine, in order to get a broader 
response due to its immunosuppressive role as well as 
the capacity to induce IL-10 expression [35].
Besides, elafin, an endogenous protease inhibitor, 
has also been orally administered using L. lactis and L. 
casei as delivery vectors, observing a restoration of colon 
homeostasis in mice [11, 36, 37]. Elastin, which is dimin-
ished in patients with IBD, has a pleiotropic and anti-
inflammatory role in healthy human gut [11, 36, 37]. 
Recently, two other anti-inflammatory molecules named 
secretory leukocyte protease inhibitor (SLPI) and the 
enzyme 15-lipoxygenase-1 (15-LOX-1) secreted by L. 
lactis have shown the ability to notably reduce the intesti-
nal inflammation in mice [37, 38].
Other models used for the local display in the mice gut 
of therapeutic protein are Lactobacillus gasseri and L. 
casei both expressing superoxide dismutase (SOD) [39, 
40]. As it happens with catalase, SOD action neutralizes 
ROS species and their derived inflammatory effect.
Fig. 1 Schematic representation of the use of LAB for biomedical applications using the oral administration pathway
Page 6 of 12Cano‑Garrido et al. Microb Cell Fact  (2015) 14:137 
Diabetes
Some articles have also been published exploring the 
potential of food-grade bacteria for the treatment of 
diabetes (Table 1). In this context, Ng and collaborators 
proved that L. lactis is able to secrete an insulin analog 
in vitro [41], promoting the expected biological effect on 
target adipocytes. Some years later, Agarwal et  al. have 
described a successful in  vivo assay with rats based on 
the oral delivery of glucagon like peptide-1 (GLP-1) using 
again L. lactis as delivery platform [42]. Briefly, GLP-1 
has emerged as a promising therapeutic peptide for type 
2 diabetes treatment, being a compound that is synthe-
sized by the GIT for the maintenance of glucose homeo-
stasis. Up to now, GLP-1 has been administered through 
injection, being necessary one administration at least 
once a week. Interestingly, Agarwal et al. have observed 
that once recombinant L. lactis secreting GLP-1 is orally 
administered in rats, a reduction in blood glucose levels 
and an important increase in insulin take place [42].
Nowadays, it is widely accepted that current treatments 
based on insulin replacement for type 2 diabetes have 
important weak aspects [42]. On the one hand, the auto-
immune response that impairs β-cells in pancreas is not 
inhibited [42]. On the other hand, insulin injection can-
not prevent important associated complications to diabe-
tes. Therefore, different therapeutic approaches based on 
immunotherapies are also being explored, being the use 
of antigen-based immunotherapies the most promising 
for this autoimmune disease. A 24 amino-acid peptide 
derived from human HSP60 has demonstrated to be a 
convenient alternative for the modulation of the immu-
nological attack on β-cells in mouse [43]. This peptide 
was successfully orally administered using recombinant 
L. lactis as delivery carrier, having a clear effect on the 
improvement of glucose tolerance and in the reduction 
of insulinitis and hyperglycemia [43]. In addition, another 
study has been recently published describing the admin-
istration of a L. lactis strain delivering antigens such as 
pro-insulin or glutamic acid decarboxylase in combina-
tion with IL-10 and anti-CD3 as an appealing method to 
improve the induction of antigen-specific tolerance for 
the treatment of the type 1 diabetes [23, 44, 45]. Another 
study has been recently followed the oral administration 
of L. lactis secreting two major auto-antigens of type 1 
diabetes, named glutamic acid decarboxylase (GAD65) 
and tyrosine phosphatase-like protein ICA512 (IA-2) in 
mouse models [23, 46]. In this study, modified versions of 
GAD65 and IA-2 have been successfully used in combi-
nation with human IL-10 cytokine [23, 46].
Cancer
Cancer has a huge relevance in human health due to its 
growing incidence in developed countries. The strategies 
for effective cancer treatment under study are countless 
and the use of LAB has recently appeared in this field.
Cancer development and progression have been 
broadly related with chronic inflammation processes 
produced by external factors such as infection, radia-
tion, unbalanced diet, obesity, tobacco or the exposure to 
other environmental pollutants [47]. Thus, in principle, 
any strategy aimed to treat chronic inflammation could 
produce also a positive outcome in cancer occurrence. In 
this regard, the use of LAB organisms for colorectal can-
cer prevention has been explored using mainly colorectal 
cancer murine models [48]. Some examples of the strains 
used with this purpose are Bifidobacterium lactis [49], 
L. casei strain Shirota [50], B. longum BB536 [51], Lac-
tobacillus acidophilus Delvo Pro LA-1 [52], Lactobacillus 
rhamnosus GG [53] or Propionibacterium freudenreichii 
[54] but many others rendered similar results, showing a 
significant decrease in cancer development. It is impor-
tant to note although the significant number of LAB 
showing promise in in vitro and in animal models that no 
conclusive studies have been carried out in humans.
On the other hand, interesting studies regarding bio-
distribution of the microbial vectors in mice models illus-
trates the capacity of some food grade species to reach 
solid tumors, where they are able to accumulate and pro-
liferate after intravenous administration [55, 56]. This 
behavior has been related with the hypoxic environment 
exhibited in the tumors. In such atmosphere anaerobic 
bacteria selectively grow [55, 56]. This capacity has been 
exploited in B. longum to propose an anti-breast cancer 
strategy based on the recombinant production of cyto-
sine deaminase in the solid tumor after the intravenous 
administration of the microbial vector. The enzyme com-
bined with the administration of the 5-fluorocytosine 
(5FC) would result in a locally high concentration of the 
reaction product, 5-fluorouracyl (5FU) [57]. Another 
example using Bifidobacterium adolescentis expressing a 
recombinant endostatin showed how this safe vector was 
able to selectively inhibit angiogenesis and tumor growth 
in tumor mice models after its intravenous administra-
tion [58]. These studies reinforce the capability of these 
microorganisms’ genera, classified according to QPS 
standards, as potential drug delivery systems for cancer 
treatment. The protein secreted by the live vector will be 
more stable than those naked soluble proteins intrave-
nously administered. However, as previously mentioned, 
the intravenous injection of LAB have important adverse 
effects. Thus, the delivery of such live vectors at mucosal 
level would be much more appropriate. In this context, 
the potential use as orally administered drug delivery 
vector with a natural selectivity for solid tumors has also 
been explored (Table  1). Recombinant B. breve orally 
administered in mice are able to effectively translocate 
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the GIT and colonize solid tumors at the same levels than 
intravenously administered ones [59]. Interestingly, the 
crossing of the GIT by the recombinant B. breve, involv-
ing an increased permeability of the GIT epithelia didn’t 
promote the crossing of potentially pathogenic bacteria 
present in the regular gut flora [59].
Besides, LAB can also be orally administered taking 
advantage of their natural niche in the body to develop 
prophylactic strategies against colon cancer without the 
need of the GIT translocation. In this sense a recombi-
nant L. lactis producing catalase has shown a protective 
effect in chemically induced colon cancer in mice models 
[60]. Tumor cells are characterized by an increased pro-
duction of ROS such as hydrogen peroxide (H2O2), that 
actively participate in enhancing tumour invasion and 
proliferation. Thus, the administration of L. lactis pro-
ducing catalase, an enzyme with an antioxidant activity, 
decreases H2O2 levels and, consequently, reduces colonic 
damage and inflammation [60]. Interestingly, since the 
oxidative stress associated to an increase of ROS levels 
is also characteristic of gastrointestinal pathologies, the 
approach developed in this study can be used also as a 
therapy for the treatment of IBD. Recently, some articles 
have been published using the administration of L. lactis 
expressing human papillomavirus E7 oncoprotein (HPV-
16 E7) for the treatment of cervical cancer. In one of these 
articles, E7 protein has been produced by a secretion 
SICE plasmid and administrated to mice with tumours. 
Results show that administration of recombinant bac-
teria provokes a slightly diminution of tumour volume 
and an antigen-specific immune response [15]. In other 
studies these food-grade bacteria have been administered 
in mice via intranasal expressing HPV-16 E7 anchored 
to its surface [61, 62]. In one case, E7 protein has been 
combined with calreticulin-E7 administration induc-
ing >80 % of tumour suppression in mice [61]. In a sec-
ond approach, recombinant lactococci have been tested 
for the simultaneous delivery of E7 protein and murine 
interleukin-12 (IL-12) DNA [62], observing that this new 
strategy combining the delivery of both the therapeutic 
molecules and antigens has a high potential. Finally, E7 
protein effect has also been investigated using L. casei as 
mucosal delivery vector in mice [63].
Infectious diseases
Historically vaccines have been based on attenuated 
pathogenic microorganisms [64, 65]. However, this 
approach has three important drawbacks: (a) difficul-
ties on the construction of stable attenuated mutants; 
(b) presence of residual virulence in attenuated patho-
gens; (c) risk of genetic reassortment between the vac-
cine strain and the wild type. Besides, although pure 
antigens have also been used for vaccination purposes, 
these molecules have a low or non-existing immune 
response, especially because their rapid degradation and 
their poor adsorption in  vivo [66]. Thus, aiming to find 
an alternative strategy, non-pathogenic LAB have also 
been explored as mucosal vaccines. Many approaches 
have been proposed in order to produce and present dif-
ferent antigens [23, 67]. Most of them have been devel-
oped in L. lactis, but also there are works using other 
LAB such as Lactobacillus zeae [68], Lactobacillus jense-
nii [69], L. plantarum [70], L. acidophilus [71], L. casei 
[72], Streptococcus gordinii [73], and Bacillus subtilis 
[74] (Table 1). It should be noted that several Lactobacil-
lus species have been exploited in this field, being some 
of them able to attach and colonise the gastrointesti-
nal mucosa, being acid-resistant and biletolerant [75]. 
Besides, the presence of these bacteria may naturally 
inhibit the pathogenic colonization of pathogenic micro-
organisms such as Helicobacter pylori [76]. However, 
although Lactobacillus seems to be one of the best can-
didates for immunization purposes, protein expression 
levels achieved are still lower than those obtained with 
L. Lactis [66, 77]. Since low protein yields cannot induce 
an immune response strong enough to trigger protection 
against infective agents, an optimal antigen presentation 
is required. That is possible with a sudden high concen-
tration of the antigen as such obtained with inducible 
approaches [67]. Nevertheless, given that it is common 
to find either insolubility or toxicity of some recombinant 
proteins during overexpression, constitutive plasmids 
can be a good alternative [78]. The use of constitutive 
plasmids is a much safer approach, being not necessary 
to add any external inducer to get the desired amount 
of protein. The use of constitutive plasmids is exempli-
fied by the expression of SspA and SspB antigens from S. 
gordonii, a major colonizer of oral hard and soft tissues, 
on the cell surface of L. lactis using P1 promoter. Both 
antigens were successfully expressed and anchored in the 
cell wall and their in  vitro ability to adhere to S. gordo-
nii surface was proven [79]. Another example is the slpA 
constitutive promoter based on S-layer protein. The very 
strong expression signal of S-layer has been proven for 
the secretion of β-lactamase using L. lactis, L. brevis, L. 
plantarum, L. gasseri and L. casei [80] and of Merozoite 
surface protein 1 (MSP1) from Plasmodium falciparum 
using L. lactis [81]. Interestingly, this last study proves 
the potential of recombinant L. lactis as an effective oral 
vaccination alternative against malaria [81]. In vivo stud-
ies with MSP1 antigen show its capacity to confer pro-
tection to the vaccinated animals [81]. Furthermore, the 
combination of the antigen with adjuvant molecules have 
been studied also aiming to achieve an increased effi-
ciency of these vaccines. An example is the coexpression 
of HIV-1 with the flagellin (FliC) of Salmonella enterica 
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in L. acidophilus. The results show that Gag (antigen 
against HIV-1) and FliC coexpression promotes Gag-
specific IgA-producing cells at the local mucosa [82]. 
Another study has been reported aiming to develop a 
vaccine against the chicken anemia virus (CAV) [71]. 
VP1 antigen produced in E. coli was fused to the bind-
ing domain of AcmA, the major autolysin of L. lactis cell 
wall, at N-terminal aiming to enhance the Lactobacillus 
immunization ability. In this case, the authors observed 
that the fusion protein remains on the cell surface at least 
5 days and that the oral administration induced a moder-
ate immune response in chicken [4, 71].
Bifidobacterium is another appealing food-grade vec-
tor. It is abundant in human gut, well recognised as pro-
biotic and with the ability to activate Th1 cell-mediated 
immune responses without antigen presentation [83]. 
Because of its biletolerance, a regulated promoter based 
on upstream sequence of bet A (a bile-inducible trans-
porter gene) has been recently developed in order to 
control gene expression specifically in the intestinal tract 
[84]. However, it should be noted that Bifidobacterium 
has a strict anaerobic metabolism making harder the 
experimentation with it.
A part from IBD, diabetes and cancer, other diseases 
have been targeted using food grade bacteria. Among 
them, interesting examples can be found in the control 
of microbial infections (Table  1). Regarding microbial 
infections neutralizing antibody fragments expressed in 
L. paracasei and L. acidphilus have been shown able to 
provide protection against Bacillus anthracis [85, 86] and 
L. paracasei against rotavirus [87] in mice. These studies 
open possibilities of generating alternative Lactobacilli 
producing antibodies against other infectious diseases 
affecting the GIT.
Besides, it is important to note that LAB and other 
organisms classified as QPS by EFSA are useful mucosal 
delivery vectors to treat not only human diseases but also 
animal diseases. Just as an example, LAB have been used 
to combat Leishmaniasis [88]. Moreover, Lactobacilli 
have also been used to design live vaccines to combat a 
wide range of diseases such as pancreatic necrosis virus 
(IPNV, a pathogen that infects wild and cultured salmo-
nids) [89, 90], a highly pathogenic avian influenza (HPAI) 
[91], and porcine epidemic diarrhea virus (PEDV) [92].
Allergic and other diseases
Some studies have combined the bacterial effect with 
an expressed antigen either for food hypersensitivity or 
aero-allergens. The administration of L. lactis displaying 
the recombinant allergen intracellularly, in the extracel-
lular space or cell wall-anchored show its capacity to 
modulate the Th2-based specific antibody responses, in 
the case of the allergen Ara h 2 against peanut allergic 
[93] and the Der p2 allergen against the dust mite allergy 
[94]. In the second study, the authors also observed a 
diminution in the cellular infiltration and inflammatory 
response.
It has been demonstrated that obesity and gut microbi-
ota composition strongly correlates [95, 96]. In addition, 
some LAB such as Lactobacillus and Bifidobacterium 
are able to improve obesity in both murine models and 
humans [96]. In this context, obesity has also been tar-
geted in mice models by the delivery of recombinant lep-
tin using LAB. Leptin is a hormone with a crucial role in 
body weight control. In this case, the capability of this 
protein to carry out its action was improved by the intra-
nasal administration of engineered L. lactis secreting the 
hormone observing a significant loss in body weight as 
well as a reduction in food intake in the treated animals 
[97].
Another example is the administration of cytokines-
secreting LAB as prophylaxis therapy, being the deliv-
ery of IL-10 for inflammatory bowel diseases [98] and of 
IL-12 for asthma [99] just a couple of examples [100].
Finally it is necessary to stress out that although most 
of the applications referred to in this revision are envis-
aged using LAB, also eukaryotic expression systems with 
a safe profile can be found in the literature. This possibil-
ity would result of interest in the cases of therapeutic pro-
teins requiring complex post-translational modifications 
to became fully functional [101]. In this regard, prokary-
otic cell factories would lack the machinery to perform 
the required processing of the recombinant protein [101]. 
A nice example is found in recombinant Saccharomyces 
cerevisiae. This yeast has been proposed as a vehicle to 
secrete proteins or peptides with a therapeutic effect in 
the gut [102]. In this sense, an orally recombinant S. cer-
evisiae displaying a salmon recombinant calcitonin on 
the yeast surface prompted a decrease in calcium levels 
in hypercalcemic rats after oral administration.
Adverse side‑effects of LAB
In the previous sections we have been focusing the atten-
tion on the positive effect of LAB as live vectors for pro-
tein delivery. However, it is important to stress that LAB 
are genetically modified organisms (GMOs). GMOs are 
widely accepted and well stablish in food industry. How-
ever, important regulatory concerns need to be addressed 
for its use as therapeutic vechicles. Specifically, LAB are 
based on expression systems carrying antibiotic resist-
ance genes as a selection marker [103]. It has been 
described that these live vectors could transfer its antibi-
otic resistances to intestinal microbiota. Although this is 
a really rare event that has not been reported in this field, 
it is an important issue to be considered. The applica-
tion of LAB as live vectors opens a broad and interesting 
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field of possibilities, but regulatory measures have to be 
considered to ensure the safety of the used strains. Up to 
now, some alternative and innovative selection markers 
have already been developed, being some of them suc-
cessfully tested and positively evaluated by several health 
authorities [23, 34, 103]. However, these alternative and 
safe selection markers need to be further explored to 
finally ensure the real possibility of using such strains for 
the problems listed above.
Besides, it should be noted that some adverse effects of 
LAB have been reported [104–106]. This indicates that, 
despite the positive therapeutic effects of these micro-
organisms and the low number of adverse effects reg-
istered, they are not completely safe. This information 
should be contextualized, since the adverse effects were 
observed in high risk groups such as critically ill and/or 
immune-compromised patients, critically sick infants, 
and postoperative and hospitalized patients [104]. Sepsis, 
fungemia and GI ischemia are the main harmful effects 
of LAB described [104]. Briefly, in this vulnerable popu-
lations LAB could interfere with the microflora giving 
rise to opportunistic infections and finally to bacterimia, 
fungimia or other medical complications. In addition, 
there are strong evidences proving that LAB, when used 
as probiotics, have anti-inflammatory effects. However, 
many reports also describe pro-inflammatory effects 
caused by such group of bacteria [107, 108]. This means 
that probiotic effect of LAB is strain dependent, being a 
factor to be considered for the choice of host strains for 
therapeutic applications.
In general terms, one can conclude that the safety of 
LAB is widely supported by the long tradition of use of 
such microbes. This safety record leads us to conclude 
that risk–benefit ratio in the prevention and treatment 
of multiple disease states is overall really high, being 
the studies reporting adverse effects scarce. Nonethe-
less, risks and benefits should be carefully considered in 
each situation, especially on those health-compromised 
patients. Besides, considering that adverse events are 
poorly documented, an accurate safety report including 
pathogenicity, infectivity, virulence and toxicity would 
help the scientific community taking decisions and more 
solid conclusions [105].
Conclusions
The irruption of nanotechnology and other innovative 
approaches have allowed the development of alternatives 
to the classical medicine aiming to overcome its inher-
ent limitations. In this regard, the exploitation of LAB as 
recombinant probiotics expressing any protein of inter-
est has strongly burst them as a promising alternative for 
the treatment of a wide range of diseases. The mucosal, 
needle-free, administration of therapeutic molecules of 
interest gives an added value to LAB. Besides, it has been 
shown that the application of these recombinant probiotic 
bacteria via intranasal, oral or genital would have a dual 
effect: a direct effect designed for the treatment of a spe-
cific disease through the expression of a recombinant pro-
tein, combined with the indirect and general effect that 
some of these safe bacteria have in health. Additionally, 
the administration of such live delivery vectors is easier 
and relatively inexpensive compared to injectable treat-
ments, being a large-scale production affordable [66]. 
Interestingly, up to now the use of LAB has been suc-
cessfully tested for a wide range of medical applications, 
mainly using animal models, being the treatment of auto-
immune diseases the most intensively investigated. These 
food-grade bacteria have also been proposed as excellent 
candidates for vaccination. There is still a lot to be done 
and a long way to reach the market, but all the articles 
published up to now let us suggest LAB as a promising 
delivery vector for a vast range of biomedical applications.
The next step will be the detailed study of all factors 
that could become an important bottleneck in the future 
implementation of LAB as effective live vectors deliver-
ing proteins of interest in situ. Important safety and regu-
latory issues still need to be addressed in depth, but some 
significant steps have already been done in this context. 
Small trials using auxotroph strains have been positively 
evaluated for the treatment of patients with Chron’s dis-
ease [26, 34]. Other aspects such as an extensive study 
of real cost and efficiency are still outstanding questions 
that need to be answered.
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